AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01909999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-operative care
Description: Postoperative care were: amoxicillin 500 mg (8-8 hours/7 days); sodic dipyrone 500mg (6-6 hours/3 days); 0.12% Chlorhexidine mouthwash
Study NCT01909999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Post-operative care
Description: Postoperative care were: amoxicillin 500 mg (8-8 hours/7 days); sodic dipyrone 500mg (6-6 hours/3 days); 0.12% Chlorhexidine mouthwash
Study NCT01569620 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Best clinical practices plus culturally targeted print materials
Description: This intervention arm includes best clinical practices (or usual care at MSSM) and the culturally relevant print materials developed for this study.
Study NCT01569620 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Best clinical practices plus standard print materials
Description: This intervention arm includes best clinical practices (or usual care at MSSM) and the standard CRC screening print materials developed by the Centers for Disease Control (CDC).
Study NCT01569620 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Best clinical practices alone
Description: This intervention arm includes best clinical practices (or standard/usual care at MSSM) and no additional print materials.
Study NCT02083536 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low Dose Fractionated Whole Abdominal Radiation Therapy
Description: A single fraction of LDFWART will be given 6-8 hours after the start of morning administration of Docetaxel for 6 cycles (the time of the start Docetaxel will be counted as the frame of reference for when the LDFWART can be given).
Study NCT02083536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Chemotherapy will consist of 6 cycles of Docetaxel. Each cycle will follow standard of care and will be scheduled every 3 weeks ± 3 days. Chemotherapy should be administered in the morning to allow 6-8 hours before Radiation Therapy. On Day 1 of each cycle, chemotherapy will consist of Docetaxel 60 mg/m² infused intravenously over 30-60 minutes (with premedication of dexamethasone 10 mg given IV 30-60 minutes prior to docetaxel administration).
Study NCT00476827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab(Avastin) 15 mg/kg every 3 weeks in combination with Capecitabine (Xeloda), 2 weeks on and 1 week off on a every 3 week cycle. until progression or unacceptable toxicity develops
Study NCT00476827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 35mg/m² IV over 60 min days 1, 8, and 15 in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle. until progression or unacceptable toxicity develops
Study NCT00476827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CPT-11
Description: CPT-11 (Irinotecan, Camptosar) - Patients being treated with an enzyme inducing antiepileptic drug (EIAED) will receive 340 mg/m² IV; others will receive 125 mg/m² IV 90 min on days 1 and 15, in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.until progression or unacceptable toxicity develops
Study NCT00476827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel (Taxol)90 mg/m2 IV over 60-90 min days 1, 8, and 15, in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.until progression or unacceptable toxicity develops
Study NCT00476827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine Tartrate
Description: Vinorelbine Tartrate (Navelbine®) 25 mg/m² IV over 10 min days 1, 8 and 15 in combination with avastin 10 mg/kg IV on days 1 and 15 of a 28-day cycle. until progression or unacceptable toxicity develops
Study NCT00476827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine (difluorodeoxycytidine, dFdC) 1000 mg/m2 IV on days 1 and 8 in combination with avastin 15 mg/kg IV on day 1 of a 21-day treatment cycle.until progression or unacceptable toxicity develops
Study NCT03370042 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: semilunar coronally positioned flap with free gingival graft
Study NCT03370042 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: semilunar coronally positioned flap alone
Study NCT02114606 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytosponge™ Cell Collection Device
Description: The Cytosponge™ Cell Collection Device (Cytosponge) is intended to collect surface cells from the esophagus. The device consists of a swallowable capsule, which dissolves in the body cavity, releasing a self-expandable sponge. The sponge is then retrieved from the esophagus using an attached cord. During the retrieval process, the sponge collects cells from the most superficial layer of the esophageal mucosa. Once removed from the body cavity, the sponge and cells are retained for investigation and/or testing. The Cytosponge™ Cell Collection Device (Cytosponge) received 510(k) clearance from the FDA on November 26, 2014 (K142695). The Cytosponge ™ Cell Collection device is a Class II product under 21 CFR 874.4710 esophagoscope (flexible or rigid) and accessories.
Study NCT02275663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacytidine
Study NCT02275663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Study NCT02275663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Study NCT02275663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: G-CSF
Study NCT02822898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaCl 0.9% in Glucose 5% with 40mEq Potassium
Description: NaCl 0.9% in Glucose 5% with 40mEq Potassium, administered at 25 mL/kg IBW/h for 48h
Study NCT02822898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucion 5%
Description: Glucion 5% (premixed solution containing 54 mmol/L sodium and 26 mmol/L potassium amongst others), administered at 25 mL/kg IBW/h for 48h
Study NCT01013194 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human Fetal Liver Cell Transplantation
Description: Human Fetal Liver Cell Transplantation. Cell source: Non-purified and non-selected fetal liver cells from fetuses aborted between the 16th and 26th week of gestation.~Infusion technique: Isolation and incannulation of the femoral artery.Splenic artery infusion under radiological guidance.~Cell infusion: between 5 and 10x10\^8 cells. Number of sessions: up to 2.
Study NCT01466127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Liquid metered-dose nasal spray, 30 IUs, administered once.
Study NCT01466127 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched nasal spray placebo
Study NCT01841814 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Bone densitometry.
Study NCT02582099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gentamicin nasal irrigation
Description: Nasal wash with gentamicin solution
Study NCT02582099 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline nasal irrigation
Description: Nasal wash with normal saline solution
Study NCT00208377 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: DePuy ASR Hip System
Description: A metal-on-metal bearing surface replacement system for use in resurfacing hip arthroplasty
Study NCT03738371 — intervention group
Intervention type: OTHER
Intervention: In situ simulation
Description: Team involved in thrombectomy procedures will be trained by in situ simulation. Simulation will reproduce the initial step of a thrombectomy procedure, i.e from from the installation of the patient to the percutaneous punch by the neuroradiologist. Simulation will be followed by a debriefing focused on the team performance. Three in situ simulation sessions will be realized by each team.
Study NCT02373358 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group yoga intervention
Description: Participants will participate in 6 90-minute yoga groups designed to promote themes related to trauma recovery (safety \& boundaries, strength \& power, assertiveness, intuition, trust, \& community) using mindfulness, breath work, and physical yoga poses.
Study NCT03234738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TP-271
Description: multiple oral doses of TP-271 or placebo, dosed once daily for 7 days, randomized 3:1, doses escalating as 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg, 2.5 mg/kg, and 3.0 mg/kg
Study NCT03234738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo is sterile 0.45% saline randomized 3:1 to receive
Study NCT02665871 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: one dose of Influenza Vaccine
Study NCT02665871 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03533062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin A
Description: botox A injection trigonal or trigonal sparing with trial of anticholinergics 6 months post operative for 3 months
Study NCT01387204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: The 2 mg dose is based on clinical data from the ongoing FTIH study in which subjects have been dosed daily for greater than 21 days, as well as preclinical toxicity data.
Study NCT01891851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435350 200 mg
Description: Each patient will receive 200 mg (2 capsules) once daily orally from Day 1 to Day 7 in Session 1 and from Day 6 to Day 12 in Session 2
Study NCT01891851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir 100 mg
Description: Each patient will receive 100 mg (1 capsule) of ritonavir twice daily orally from Day 1 until Day 15 of Session 2
Study NCT01226719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: 6 mg/kg, 60-90 minute IV infusion every 2 weeks
Study NCT01226719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m2, 2-hour IV infusion every 2 weeks
Study NCT01226719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 125 mg/m2, 1-hour IV infusion every 2 weeks
Study NCT01226719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 200 mg/m2, 2-hour IV infusion every 2 weeks
Study NCT01226719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 3200 mg/m2 IV, 48-hour continuous infusion every two weeks
Study NCT05827627 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: simulation
Description: Midwifery student directing the birth of a fetus with frank breech presentation.
Study NCT05827627 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: simulation
Description: Midwifery student directing the birth of a fetus with frank breech presentation.
Study NCT03903666 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nocturnal gaz exchanges measurement
Description: Nocturnal gaz exchanges at patient's home BRIEF neuropsychological questionnaire VINELAND-II neuropsychological questionnaire Clinical OSA assessment Dysautonomia assessment
Study NCT03096665 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood test
Description: Point of care blood analysis obtained from skin puncture
Study NCT01868633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Study NCT01868633 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03320681 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical Stimulation
Description: Percutaneous electrical nerve stimulation
Study NCT03320681 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dry Needling Stimulation
Description: Percutaneous nerve stimulation
Study NCT02611622 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LUMA ENT™
Study NCT02611622 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey
Description: Demographic and Patient Satisfaction Survey
Study NCT02611622 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Description: Demographic and Patient Satisfaction Survey
Study NCT01302821 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adenovirus-p53 transduced dendritic cell vaccine
Description: The Ad.p53 DC vaccine will be injected intradermally (through the skin) into four separate sites. The patient's vaccine will be the same dose throughout the study.
Study NCT03545438 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: LIB003
Description: LIB003 or placebo
Study NCT01302821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1-methyl-D-tryptophan
Description: Each treatment cycle is comprised of 21 days. The treatment is continuous with no breaks in between cycles. Patients would not be allowed to take any tryptophan containing supplements while participating on this study.
Study NCT03194919 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endre: a digital smoking cessation counsellor
Description: A comprehensive 25-session intervention delivered by web, e-mail and SMS-text messages. Sessions are released one each day for 18 days, and then every second day for 14 days. Intervention content is tailored based on user input and individual usage pattern. The intervention is described in detail in Holter, Johansen \& Brendryen (2016). How a fully automated eHealth program simulates three therapeutic processes: A case study. Journal of Medical Internet Research 18 (6).
Study NCT01129375 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form: matching tablet~Route of administration: oral
Study NCT02668445 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard meal containing low or high carbohydrate content
Study NCT01976104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avatrombopag (lower baseline platelet count)
Description: 60 mg avatrombopag (3 x 20 mg tablets)
Study NCT01976104 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (lower baseline platelet count)
Description: 60 mg placebo (3 x 20 mg matching placebo tablets)
Study NCT01976104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avatrombopag (higher baseline platelet count)
Description: 40 mg avatrombopag (2 x 20 mg tablets)
Study NCT01976104 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (higher baseline platelet count)
Description: 40 mg placebo (2 x 20 mg matching placebo tablets)
Study NCT04624282 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: different diseases
Description: Patients will be divided into three groups, including chronic superficial gastritis ,chronic atrophic gastritis and gastric carcinoma.
Study NCT03063931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium: Magnésium UPSA Action Continue®
Description: This clinical trial compares magnesium and placebo for the prevention of neuropathic pain induced by mastectomy assessed with a (0-10) numerical pain rating scale
Study NCT03063931 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Lactose
Description: This clinical trial compares magnesium and placebo for the prevention of neuropathic pain induced by mastectomy assessed with a (0-10) numerical pain rating scale
Study NCT00665366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: 5-, 10-, or 15-mg oral tablets in titrated doses for 12 weeks
Study NCT00665366 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0 mg, once daily, 12 weeks
Study NCT00665366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium
Description: Participant's ongoing dose
Study NCT00665366 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lithium
Description: Participant's ongoing dose
Study NCT00665366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproate
Description: Participant's ongoing dose
Study NCT00665366 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Valproate
Description: Participant's ongoing dose
Study NCT03176576 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigator (PN)
Description: Patient navigation (PN) is an intervention model designed to assist vulnerable patients in overcoming health system, personal and/or logistical barriers to care throughout the cancer care continuum. The strategic aims of PN are to reduce barriers and improve disease outcomes while also reducing distress and enhancing quality of life for the patient and family. Participants in the PN group will meet with a patient navigator.
Study NCT03176576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baseline Questionnaire
Description: Complete a baseline questionnaire online or by meeting with a member of the study team. This questionnaire has items asking about the participant's health, distress levels, satisfaction with their care at Moffitt Cancer Center, and what support services they have used since their diagnosis. This questionnaire will take about 15 to 20 minutes of their time.
Study NCT03176576 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Baseline Questionnaire
Description: Complete a baseline questionnaire online or by meeting with a member of the study team. This questionnaire has items asking about the participant's health, distress levels, satisfaction with their care at Moffitt Cancer Center, and what support services they have used since their diagnosis. This questionnaire will take about 15 to 20 minutes of their time.
Study NCT03176576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up Questionnaire
Description: After participants complete the baseline questionnaire, they will be asked to complete a follow-up questionnaire approximately 6 weeks from when they completed the baseline questionnaire. The follow-up questionnaire will take about 15 to 20 minutes to complete.
Study NCT03176576 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Follow-up Questionnaire
Description: After participants complete the baseline questionnaire, they will be asked to complete a follow-up questionnaire approximately 6 weeks from when they completed the baseline questionnaire. The follow-up questionnaire will take about 15 to 20 minutes to complete.
Study NCT03176576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Navigator Satisfaction Survey
Description: Evaluation of Patient Navigator intervention process.
Study NCT04851704 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tuning in to Kids
Description: A parenting program that includes 6 group supervisions of parents, where emotion coaching and promotion of kids emotional competence are main focus.
Study NCT01147432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04427429
Description: Single dose IV infusion up to 300mg
Study NCT01147432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Capsaicin challenge
Description: Capsaicin challenge: 110 mg (0.075% capsaicin) to be applied at pre-dose and at 2h, 5h, 8h and 24h post-dose as well as 1 week and 4 weeks post final treatment period
Study NCT01147432 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV infusion (saline) to be administered during two of the three treatment periods
Study NCT01147432 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Capsaicin challenge
Description: Capsaicin challenge: 110 mg (0.075% capsaicin) to be applied at pre-dose and at 2h, 5h, 8h and 24h post-dose as well as 1 week and 4 weeks post final treatment period
Study NCT01147432 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EMLA positive control
Description: 2g EMLA cream to be applied ONCE during study period 1
Study NCT02696837 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ETT
Study NCT02696837 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Proseal LMA
Study NCT02696837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Study NCT02696837 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Muscle Relaxant
Study NCT01129375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole
Description: Pharmaceutical form: delayed-release capsule~Route of administration:oral
Study NCT02223637 — intervention group
Intervention type: BIOLOGICAL
Intervention: Meningococcal quadrivalent CRM-197 conjugate vaccine
Description: This pregnancy registry is strictly observational. Decisions of vaccination are made by health care providers.
Study NCT04174443 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High-voltage pulsed radiofrequency
Description: 2 Hz of pulsed radiofrequency will be administered at a voltage of 70 V, temperature of 42 °C, pulse width of 20 ms, and treatment time of 600 s.
Study NCT04174443 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-voltage pulsed radiofrequency
Description: 2 Hz of pulsed radiofrequency will be administered at a voltage of 70 V, temperature of 42 °C, pulse width of 20 ms, and treatment time of 600 s.
Study NCT04174443 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low-temperature continuous radiofrequency
Description: Low-temperature continuous radiofrequency will be performed at 60 °C, with a treatment time of 270 s.